N/A N=36 Intermittent Pneumatic Compression in Women With Lipo-lymphedema (Lipedema With Swelling)
Lipedema · Lipolymphedema
Primary: Change in Circumferential Measurements Over Time — -0.5; -1.0; -1.3; -2.0 cm
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=34 Vasculera in Participants With Lipedema
Lipedema
Primary: Change in Weight From Baseline — 0.340 kilograms — p=0.473
Phase 2 N=12 Treatment of Women With Lipedema Involving Substantial Fat Knee of Women and Men With Nodular Dercum's Disease
Lipedema · Dercum Disease
Primary: The Incidence of Any Grade 3 or Greater Event Intolerable Side Effect Experienced in a Cohort — 0; 0; 0 Participants
Phase 2 N=38 RZL-012 for Dercum's Disease Lipomas
Dercum's Disease Lipomas
Primary: Efficacy - Change in Lipomas Dimensions — -15.13; -15.92 percentage of change from baseline
Phase 2 N=103 Leptin to Treat Lipodystrophy
Lipodystrophy
Primary: Percentage of Glycosylated Hemoglobin at Baseline, 6 Months, and 12 Months on Treatment With Metreleptin — 8.4; 8.1; 6.6; 7.2 percentage of glycated hemoglobin — p=<0.001
Phase 2 N=5 Efficacy, Safety and Tolerability of ISIS 304801 in People With Partial Lipodystrophy With an Open-Label Extension
Lipodystrophy
Primary: Change in Log 10 Fasting Triglycerides. — 0.1; -0.2 log 10 mg/dl
Phase 2 N=62 Phase 2 Study for the Treatment of Superficial Lipomas
Lipoma
Primary: Number of Participants With Adverse Events (AEs) — 12; 13; 14; 12 participants
N/A N=20 Laser Assisted Liposuction and Facial Autologous Fat Grafting With the LipoLife System
Laser Assisted Liposuction
Primary: Correct Identification of Before and After Photographs — 20 Participants
N/A N=18 Imaging Biomarkers of Lymphatic Dysfunction
Secondary Lymphedema
Primary: Assessing a Change in Bioimpedance Spectroscopy (BIS) — 1.3; 1.8 Change of score on a scale
Phase 2 N=54 Ubenimex in Adult Patients With Lymphedema of The Lower Limb (ULTRA)
Lymphedema
Primary: Change in Skin Thickness of the Calf of the Most Affected Leg, Measured by Skinfold Calipers — -6.83; -7.75 mm
Phase 2 N=14 A Dose Escalation Study Using Collagenase Clostridium Histolyticum in the Treatment of Lipoma
Lipoma
Primary: Change in Visible Surface Area of the Lipoma — -31.69; -47.57; -52.42; -66.60 Percent change from baseline
Phase 4 N=50 Lymphedema Study for Arm or Leg Lymphedema
Lymphedema
Primary: Part 1: Count of Participants Able to Complete Ketoprofen Treatment — 50 Participants
Phase 2 N=82 Acupuncture for Chronic Lymphedema
Breast Cancer With Chronic Lymphedema
Primary: Lymphedema as Measured at Baseline and at 6 Weeks — 4.74; 4.82; 4.29; 4.76 cm
N/A N=40 Ectopic Lipid Deposition and Insulin Resistance in After Treatment of Acromegaly
Acromegaly
Primary: Change in Liver Fat — 0.03 Lipid/water ratio
N/A N=21 LLLT Combined With CDT in Breast Cancer-Related Lymphedema
Breast Cancer · Lymphedema
Primary: Arm Volume — 1.48; 1.58 cm^3
Phase 2 N=19 Double Blind Study to Evaluate the Efficacy of Collagenase Histolyticum in the Treatment of Lipoma
Lipoma
Primary: Percent Change From Baseline in Surface Area of the Lipoma at Six Months — -81.277; 2.053 percentage change from baseline — p=<0.0001
Phase 2 N=259 EN3835 for the Treatment of Edematous Fibrosclerotic Panniculopathy (Commonly Known as Cellulite)
Edematous Fibrosclerotic Panniculopathy · Cellulite
Primary: Number of Participants That Were 2-level Composite (CR-PCSS and PR-PCSS) Responders During the Observation Phase — 19; 0; 16; 0 Participants
N/A N=63 Cellular Dynamics of Subcutaneous Fat Distribution in Obese Women
Obesity · Metabolic Syndrome
Primary: In Vivo Adipose Cell Formation (Adipogenesis) — -0.3; 1.8; -1.2; 2.1 percent
Phase 2 N=10 Association of Beta-2 Adrenergic Agonist and Corticosteroid Injection in the Treatment of Lipomas
Lipoma
Primary: The Average Percent Volume Reduction in the Lipoma. — 50 Percent Volume reduction (cc^3)
N/A N=24 Study to Evaluate the Safety and Effectiveness of Dayspring for Lower Extremity Lymphedema
Lymphedema · Lymphedema Lower Extremity · Chronic Venous Insufficiency
Primary: LYMQOL (LYMphedema Quality of Life) ***All Relevant Time Points Used in the Calculation in the Time Frame (e.g., Baseline and 3 Months).*** — .83 units on a scale
N/A N=17 Leptin for Abnormal Lipid Kinetics in HIV Lipodystrophy Syndrome
HIV Lipodystrophy
Primary: Rate of Total Lipolysis — 0.649; 0.767 mmol FFA/kg/h
N/A N=13 Upper Extremity Lymphatic Mapping for Breast Cancer Patients
Breast Cancer · Axillary Lymph Node Dissection
Primary: Number and Prevalence of Metastases of Blue Nodes in the ALND Specimen (Nodes Draining the Breast). — 0 participants
Phase 4 N=50 Low Level Laser Treatment and Breast Cancer Related Lymphedema
Lymphedema
Primary: LDex Change- — 28.0; 17.8; 22.2 LDex
Phase 3 N=25 Trial of Leptin Replacement Therapy in Patients With Lipodystrophy
Hypoleptinemia · Generalized Lipodystrophy · Partial Lipodystrophy
Primary: Fasting Serum Triglycerides — 203; 304 mg/dL — p=0.2572
N/A N=60 Treatment of Subcutaneous Adipose Tissue in the Thighs Using High Intensity Focused Ultrasound
Treatment of Adipose Tissue in the Thighs
Primary: Clinical Improvement in Thigh Circumference — -1.22; -0.59 centimeter
N/A N=4 HIV Acquired Lipodystrophy (HAL) Classification, Measurement and Fat Response to Thiazolidinedione (TZD) (Pioglitazone)
HIV Infections
Primary: Percent of Liver Fat Pre/Post Challenge With Daily Pioglitazone 45 mg
Phase 3 N=153 Real World CCH Study in Adult Females With Cellulite
Edematous Fibrosclerotic Panniculopathy (EFP) · Cellulite
Primary: The Proportion of Participants With Improved (+1 or Better) Score on I-GAIS for Either Posterolateral Thigh — 58 Participants
N/A N=75 Lymphedema Prophylaxis in Breast Cancer Survivors Who Show Early Evidence of High-risk Status
Lymphedema · Breast Cancer
Primary: Number of Participants With Successful Assessment of Lymphedema by Multiple Frequency Bioimpedance Spectroscopy — 19; 21; 22 participants
Phase 3 N=342 Selinexor in Advanced Liposarcoma
Dedifferentiated Liposarcoma
Primary: Phase 3 Double Blind: Progression-free Survival (PFS) as Per Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1 — 2.83; 2.07 Months — p=0.0114
N/A N=1,390 Real-world Study of Dedifferentiated Liposarcoma Patients in China
Dedifferentiated Liposarcoma
Primary: Cohort 1: Overall Survival — 13.4; 11.9; 8.1 months